Lyra Therapeutics (LYRA) Gains from Sales and Divestitures (2022 - 2025)
Quarterly Gains from Sales and Divestitures fell 52.35% to $41250.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41250.0 through Dec 2025, down 52.35% year-over-year, with the annual reading at $41250.0 for FY2025, 52.35% down from the prior year.
Lyra Therapeutics' Gains from Sales and Divestitures history spans 4 years, with the latest figure at $41250.0 for Q4 2025.
- Gains from Sales and Divestitures came in at $41250.0 for Q4 2025, up from $34182.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $365121.0 in Q1 2025 to a low of $1302.0 in Q2 2022.
- The 4-year median for Gains from Sales and Divestitures is $21486.5 (2024), against an average of $54122.9.
- Year-over-year, Gains from Sales and Divestitures soared 1722.65% in 2024 and then crashed 52.35% in 2025.
- Lyra Therapeutics' Gains from Sales and Divestitures stood at $1953.0 in 2022, then soared by 260.52% to $7041.0 in 2023, then soared by 1129.57% to $86574.0 in 2024, then plummeted by 52.35% to $41250.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Gains from Sales and Divestitures are $41250.0 (Q4 2025), $34182.0 (Q3 2025), and $15104.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Lyra Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41,250.00 |
| Dec 31, 2025 | 41,250.00 |
| Sep 30, 2025 | 34,182.00 |
| Sep 30, 2025 | 34,182.00 |
| Jun 30, 2025 | 15,104.00 |
| Jun 30, 2025 | 15,104.00 |
| Mar 31, 2025 | 365,121.00 |
| Mar 31, 2025 | 365,121.00 |
| Dec 31, 2024 | 86,574.00 |
| Dec 31, 2024 | 86,574.00 |
| Sep 30, 2024 | 27,869.00 |
| Sep 30, 2024 | 27,869.00 |
| Jun 30, 2024 | 27,869.00 |
| Jun 30, 2024 | 27,869.00 |
| Mar 31, 2024 | 128,333.00 |
| Mar 31, 2024 | 128,333.00 |
| Dec 31, 2023 | 7,041.00 |
| Dec 31, 2023 | 7,041.00 |
| Sep 30, 2023 | 7,041.00 |
| Sep 30, 2023 | 7,041.00 |
| Jun 30, 2023 | 7,041.00 |
| Jun 30, 2023 | 7,041.00 |
| Mar 31, 2023 | 7,041.00 |
| Mar 31, 2023 | 7,041.00 |
| Sep 30, 2022 | 1,953.00 |
| Sep 30, 2022 | 1,953.00 |
| Jun 30, 2022 | 1,302.00 |
| Jun 30, 2022 | 1,302.00 |